Fat Burning Steroids Powder Rimonabant Safe Pass
Détail rapide
Nom du produit: Rimonabant
Synonymes: ACOMPLIA;RIMONABANT;RIMONABANT(ACOMPLIA,SR141716);5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide;1H-Pyrazole-3-carboxamide, 5-(4-chlorophényle)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-;5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide;UN 281;Sr 141716
CAS: 168273-06-1
MF: C22H21Cl3N4O
MW: 463.79
Essai 99%
Apparence: Poudre blanche
Usage Weight loss powders/ Rimonabant is a selective antagonist
catégories de produits: Weight Loss;SR141716
Rimonabant Description:
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that has been withdrawn from the market due to potentially serious side effects. It was approved for use in Europe and other countries, but never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It has also been shown to be a μ-opioid receptor antagonist (possibly the contributing factor in its reported dysphoric qualities).Its main effect is reduction in appetite.
An experimental wonder drug, Rimonabant, helps you lose weight, quit smoking and it also helps protect your heart. Trials have shown that 33% of people on Rimonabant lost 10% of body weight and kept their weight down for two years – this is a record, no other diet drug has managed to keep a person’s weight down for so long.
The second 33% lost 5% of body weight and kept it down. As well as keeping you lean, the drug also helps you quit the smoking habit. This will be of great interest for many smokers who are afraid to give up because they say they will put on loads of weight if they do.
Rimonabant Application:
Rimonabant (trade name Acomplia) is an anorexia anti-obesity drug that has been eliminated due to potentially serious side effects. It was approved for use in Europe and other countries, but never approved in the United States. Rimonabant is the inverse agonist of cannabinoid receptor CB1. It has also been shown to be a μ-opioid receptor antagonist (which may be a contributing factor to its reported anxiety symptoms) whose primary role is to reduce appetite.
Directeur commercial